Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells

Circulation

Volumn 99, Issue 15, 1999, Pages 2034-2040

  Benzing, Thomas ^a   Fleming, Ingrid ^a   Blaukat, Andree ^b   Müller Esterl, Werner ^b   Busse, Rudi ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Angiotensin; Bradykinin; Cells; Enzymes

Indexed keywords

ANGIOTENSIN; BRADYKININ; BRADYKININ B2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; RAMIPRILAT;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SWINE; VASCULAR ENDOTHELIUM;

EID: 0033586646     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.15.2034     Document Type: Article

References (32)

1. Fleming I, Bauersachs J, Busse R. Paracrine functions of the coronary vascular endothelium. Mol Cell Biochem. 1996;157:137-145.
2. Wever RMF, Lüscher TF, Cosentino F, Rabelink TJ. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation. 1998;97: 108-112.
3. Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard ACG. Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation. 1996;94:258-265.
4. ELUCID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbummuria. Lancet. 1998;349:1787-1792.
5. Sihm I, Schroeder AP, Aalkjaer C, Holm M, Morn B, Mulvany MJ, Thygesen K, Lederballe O. Regression of media-to-lumen ratio of human subcutaneous arteries and left ventricular hypertrophy during treatment with an angiotensin-converting enzyme inhibitor-based regimen in hypertensive patients. Am J Cardial. 1995;76:38E-40E.
6. Clozel J-P, Kuhn H, Hefti F. Vascular protection with cilazapril in hypertension. J Cardiovasc Pharmacol. 1992;19:S28-S33.
7. Vanbelle E, Meurice T, Tio FO, Corseaux D, Dupuis B, Mcfadden EP, Lablanche JM, Bauters C, Bertrand ME. ACE inhibition accelerates endothelial regrowth in vivo: a possible explanation for the benefit observed with ACE inhibitors following arterial injury. Biochem Biophys Res Commun. 1997:231:577-581.
8. Wiemer G, Schölkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 1991;18:558-563.
9. Busse R, Lamontagne D. Endothelium-derived bradykinin is responsible for the increase in calcium produced by angiotensin-converting enzyme inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 1991;344:126-129.
10. Bonner G, Preis S, Schunk U, Toussaint C, Kaufmann W. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol. 1990;15:S46-S56.
11. Schmaier AH, Kuo A, Lundberg D, Murray S, Cines DB. The expression of high molecular weight kininogen on human umbilical vein endothelial cells. J Biol Chem. 1988;263:16327-16333.
12. van Iwaarden F, de Groot PG, Sixma JJ, Berrettini M, Bouma BN. High molecular weight kininogen is present in cultured human endothelial cells: localization, isolation and characterization. Blood. 1988;71: 1268-1276.
13. van Iwaarden F, de Groot PG, Bouma N. The binding of high-molecular weight kininogen to cultured human endothelial cells. J Biol Chem. 1988;263:4698-4703.
14. Hecker M, Pörsti I, Bara AT, Busse R. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level. Br J Pharmacol. 1994;111:238-244.
15. Hecker M, Blaukat A, Bara A, Müller-Esterl W, Busse R. ACE inhibitor potentiation of bradykinin-induced venoconstriction. Br J Pharmacol. 1997;121:1475-1481.
16. AbdAlla S, Buschko J, Quitterer U, Maidhof A, Haasemann M, Breipol G, Knolle J, Müller-Esterl W. Structural features of the human bradykinin B, receptor probed by agonists, antagonists, and anti-idiotypic antibodies. J Biol Chem. 1993;268:17277-17285.
17. Blaukat A, AbdAlla S, Lohse MJ, Müller-Esterl W. Ligand-induced phosphorylation/dephosphorylation of the endogenous bradykinin B2 receptor from human fibroblasts. J Biol Chem. 1996;271:32366-32374.
18. Smart EJ, Ying YS, Mineo C, Anderson RGW. A detergent-free method for purifying caveolae membrane from tissue culture cells. Proc Natl Acad Sci U S A. 1995;92:10104-10108.
19. Fleming I, Fisslthaler B, Busse R. Calcium signaling in endothelial cells involves activation of tyrosine kinases and leads to activation of MAP kinase. Circ Res. 1995;76:522-529.
20. Fleming I. Hecker M, Busse R. Intracellular alkalinization induced by bradykinin sustains activation of the constitutive nitric oxide synthase in endothelial cells. Circ Res. 1994;74:1220-1226.
21. Weintraub WH, Negulescu PA, Machen TE. Calcium signalling in endothelia: cellular heterogeneity and receptor internalization. Am J Physiol. 1992;263:C1029-C1039.
22. Lamontagne D, Busse R. Endothelium-derived bradykinin is responsible for the increase in calcium produced by angiotensin-converting enzyme inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 1991;344:126-129.
23. Böhm SK, Grady EF, Bunnett NW. Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. Biochem J. 1997; 322:1-18.
24. 1 MF-2 smooth muscle cells. J Biol Chem. 1997;272: 17858-17866.
25. 2 receptor in caveolae. J Cell Sci. 1998;111: 917-928.
26. Schnitzer JE, McIntosh DP, Dvorak AM, Liu J, Oh P. Separation of caveolae from associated microdomains of GPI-anchored proteins. Science. 1995;269:1435-1439.
27. Stan RV, Roberts WG, Predescu D, Ihida K, Saucan L, Ghitescu L, Palade GE. Immunoisolation and partial characterization of endothelial plasmalemmal vesicles (caveolae). Mol Biol Cell. 1997;8:595-605.
28. Leeb-Lundberg LMF, Mathis SA, Herzig MCS. Antagonists of bradykinin that stabilize a G-protein-uncoupled state of the B2 receptor act as inverse agonists in rat myometrial cells. J Biol Chem. 1994;269: 25970-25973.
29. Busse R, Fleming I, Hecker M. Endothelium-derived bradykinin: implications for ACE inhibitor therapy. J Cardiovasc Pharmacol. 1993;22: S31-S36.
30. Busse R, Fleming I. Molecular responses of endothelial tissue to kinins. Diabetes. 1996;45:S8-S13.
31. 2 receptors and angiotensin I-converting enzyme in CHO cells. Circ Res. 1997;81:848-856.
32. 2 receptor. J Biol Chem. 1998;273: 1309-1315.